BCG was proud to send a team of experts to San Francisco alongside the J.P. Morgan Healthcare Conference, January 13-15, 2025, to engage with leading experts in health care innovation and investment.
J.P. Morgan Health Care Conferenceは業界最大のヘルスケア投資シンポジウムで、そこには業界のリーダー、急成長中の新興企業、革新的テクノロジーの開発者、投資コミュニティのメンバーなどが一同に会します。
Learn more about BCG’s latest work with health care clients.
BCG and Zeiss developed an application to give prospective patients fast, accurate, validated answers about elective treatments.
LEARN MORE
How BCG used a cascaded and holistic organization-design approach to help a global biotech firm reduce its gross labor and non-labor costs by 20%.
LEARN MORE
BCG X partners to leverage new AI tools and platform to enhance clinical trials, speeding up medical innovations, life-changing therapies, and patient outcomes.
LEARN MORE
Our GenAI Collaboration with Merck
This year, BCG launched a collaboration with Merck aimed at advancing the discovery and assessment of novel drug targets for chronic and degenerative diseases through AI.
BCG’s second annual report reviews the growth of new drug modalities over the past year and addresses the potential impact on the biopharmaceutical industry.
New GenAI offerings can benefit virtually every aspect of an organization, boosting efficiency and productivity in areas ranging from R&D to commercial activities.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Costs for genomic sequencing have dropped steeply, making new types of genetic tests more accessible and changing the business model for the labs that run them.
The rise of GenAI brings tremendous opportunity. But to cut through the hype and identify future winners, investors should focus on four innovation hot spots.
グローバルなバイオ医薬品会社のデータ・テクノロジー最高責任者（CDTO）が、バリューチェーン全体にデジタル機能を導入し、患者の治療結果に注力することについて語ります。
